SCHEMBL25979759

SCHEMBL25979759

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4c(c3)oc3cc(-c5cccc(N(c6ccccc6)c6ccc7ccccc7c6)c5)ccc34)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.38
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.38
HSD17B1 P14061 2/20 0.33
HSD17B2 P37059 2/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
MAPT P10636 5/20 0.33
HPGD P15428 3/20 0.33
CYP3A4 P08684 3/20 0.32
CYP2D6 P10635 3/20 0.32
CYP2C9 P11712 3/20 0.32
CYP2C19 P33261 3/20 0.32
HCRTR1 O43613 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25979640 0.96 ALDH1A1 (0.39) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL25979225 0.95 ALDH1A1 (0.35) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL26779239 0.95 MEN1 (0.40) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL26779230 0.95 MEN1 (0.40) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL25979457 0.95 MEN1 (0.40) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL25979930 0.93 CYP1A2 (0.41) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL25979483 0.93 MEN1 (0.40) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL25979762 0.92 MAPT (0.36) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL26779232 0.92 MAPT (0.36) CYP1A2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL25979467 0.92 MEN1 (0.41) CYP1A2ALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 CYP1A2 5/4885ALDH1A1 9/4885MEN1 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.